trial

Fingolimod in Schizophrenia Patients

NCTId NCT01779700
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 40 (actual)
Sponsored by Indiana University
Primary completion 2016-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Quadruple
Start
2013-01
Primary completion
2016-08
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Fingolimod

Sponsors

Indiana UniversityLead Sponsor

Investigators

2
Alan Breier, MDPrincipal Investigator
Michael Francis, MDPrincipal Investigator

Sites

3 total
Indianapolis, United StatesIndianapolis, United StatesIndianapolis, United States

Linked catalysts

1
Fingolimod in Schizophrenia Patients — primary completion2016-08

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE2
Primary Completion Date
2016-08
Status
COMPLETED
relationships
The graph out of here
drug
Fingolimod
drug
lead_sponsor
Indiana University
company
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
investigator
Alan Breier, MD
person
Michael Francis, MD
person